Comparison of positron emission tomography with [18F]FDG and [68Ga]DOTATOC in recurrent differentiated thyroid cancer: Preliminary data

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 1, 2010, Pages 76-83

  Middendorp, M ^a   Selkinski, I ^a   Happel, C ^a   Kranert, W T ^a   Grunwald F ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Positron emission tomography; Thyroid neoplasms

Indexed keywords

DOTATOC GA 68; FLUORODEOXYGLUCOSE F 18; IODINE 131; RADIOACTIVE IODINE; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; THYROGLOBULIN; THYROTROPIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; THYROID CANCER; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; YOUNG ADULT;

EID: 77952508806     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Stokkel MPM, Duchateau CSJ, Dragoiescu C. The value of FDG-PET in the follow-up of of differentiated thyroid cancer: a review of the literature. QJ Nucl Med Mol Imaging 2006;50:78-87.
2. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. Thyroid 2002;12:707-711
3. Grünwald F, Kälicke T, Feine U, Lietzenmayer R, Scheidhauer K, Diedein M et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-1552
4. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999;40:986-992
5. Al-Nahhas A: Dedifferentiated thyroid carcinoma: the imaging role of 18F-FDG PET and non-iodine radiopharmaceuticals. Nucl Med Commun 2004;25:891-895.
6. Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T et al. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 2004;31:491-498
7. Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med 2007;48:889-895
8. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007;48:221-226
9. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007;3:112-121
10. Choi MY, Chung JK, Lee HY, So Y, Park do J, Jeong JM et al. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: a single-center study of 108 patients. Ann Nucl Med 2006;20:547-552
11. Iagaru A, Masamed R, Singer PA, Conti PS. 2-Deoxy-2-[18F] fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. Mol Imaging Biol 2006;8:309-314 (Pubitemid 44446025)
12. Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, Rampin L et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 2006;60:409-413
13. Palmedo H, Bucerius J, Joe A, Strunk H, Hording N, Meyka S et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616-624
14. Alzahrani AS, Mohamed GE, Al Rifai A, Al-Sugair A, Abdel Salam SA, Sulaiman OM et al. Role of [18F] fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. Endocr Pract 2006;12:152-158
15. Chen YK, Liu FY, Yen RF, Kao CH. Compare FDG-PET and Tc-99m tetrofosmin SPECT to detect metastatic thyroid carcinoma. Acad Radiol 2003;10:835-839
16. Ain KB, Taylor KD, Tofiq S, Venkataraman G. Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 1997;82:1857-1862 (Pubitemid 127495200)
17. Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P et al. Value of 111In-DOTA-DPhel-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:1144-1151
18. Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, Virgolini I. 99mTc-Depreotide Scintigraphy Versus 18F-FDG-PET in the Diagnosis of Radioiodine-Negative Thyroid Cancer. J Clin Endocrinol Metab 2006;91:3997-4000.
19. Sarlis NJ, Gourgiotis L, Guthrie LC, Galen B, Skarulis MC, Shawker TH et al. In-III DTPA-Octreotide Scintigraphy for Disease Detection in Metastatic Thyroid Cancer: Comparison with F-18 FDG Positron Emission Tomography and Extensive Conventional Radiographic Imaging. Clin Nucl Med 2003;28:208-217
20. Stokkel MPM, Verkooijen RB, Smit JWA. Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value. Eur J Nucl Med Mol Imaging 2004;31:950-957
21. Görges R, Kahaly G, MüUer-Brand J, Mäcke H, Roser HW, Bockisch A. radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001;11:647-659
22. Teunissen JJM, Kwekkeboom DJ, Kooij PPM, Bakker WH, Krenning EP. Peptide Receptor Radionuclide Therapy for Non-Radioiodine-Avid Differentiated Thyroid Carcinoma. J Nucl Med 2005;46:107S4S.
23. Teunissen JJM, Kwekkeboom DJ, Krenning EP: Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends Endocrinol Metab 2006;17:19-25.
24. Stokkel MPM, Verkooijen RB, Bouwsma H, Smit JW. Six month follow-up after 111In-DTPA-octreotide therapy in patients with progressive radioiodine non-responsive thyroid cancer: a pilot study. Nucl Med Commun 2004;25:683-690
25. Waldherr C, Schumacher T, Pless M, Crazzolara A, Maecke HR, Nitzsche EU et al. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using. Nucl Med Commun 2001;22:673-678
26. Gabriel M, Froehlich F, Decristoforo C, Ensinger C, Donnemiller E, von Guggenberg E et al. 99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans. Eur J Nucl Med Mol Imaging 2004;31:330-341
27. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-282
28. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46(Suppl): 172-178
29. Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338-1347
30. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-1626
31. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518
32. Valli N, Catargi B, Ronci N, Leccia F, Guyot M, Roger P et al. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy. Thyroid 1999;9:583-589
33. Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 1996;81:2541-2544
34. Garin E, Devillers A, Le Cloirec J, Bernard AM, Lescouarc'h J, Herry JY et al. Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 1998;25:687-694
35. Görges R, Kahaly G, Müller-Brand J, Mäcke H, Walgenbach S, Bruns C et al. Somatostatin receptor status in non-medullary thyroid carcinoma. Nuklearmedizin 1999;38:15-23.
36. Kohlfuerst S, Igerc I, Gallowitsch HJ, Gomez I, Kresnik E, Matschnig S et al. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases? Thyroid 2006;16:1113-1119
37. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002;29:641-647
38. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-1995
39. Haslinghuis LM, Krenning EP, De Herder WW, Reijs AE, Kwekkeboom DJ. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer. J Endocrinol Invest 2001;24:415-422